




















Filed • Approved

 antibody  protein  small molecule

As of Sep.30, 2017








Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		<b>KRN321</b> <b>Darbepoetin Alfa</b> <b>Injection</b>	Long-Acting Erythropoiesis Stimulating Agent	Renal Anemia (on Dialysis)	NDA in preparation in CN	Kirin-Amgen	
				Renal Anemia	Filed in ID		
		<b>KRN1493</b> <b>Cinacalcet</b> <b>Hydrochloride</b> <b>Oral</b>	Calcium Receptor Agonist	Secondary Hyperparathyroidism	Filed in BN	Licensed from NPS	
		<b>©KHK7580</b> <b>Evocalcet</b> <b>Oral</b>	Calcium Receptor Agonist	Secondary Hyperparathyroidism	Filed in JP	Licensed from Mitsubishi Tanabe Pharma	
Oncology		<b>Granisetron</b> <b>Patch</b>	5-HT <sub>3</sub> Serotonin Receptor Antagonist	Chemotherapy induced Nausea and Vomiting	Filed in MY	Licensed from Solasia Pharma	
Immunology /Allergy		<b>©KHK4563</b> <b>Benralizumab</b> <b>Injection</b>	Anti-IL-5 Receptor Humanized Antibody	Asthma	Filed in JP	In-House	POTELLIGENT® Jointly Developed with AstraZeneca/MedImmune NDA holder is AstraZeneca
		<b>KHK4827</b> <b>Brodalumab</b> <b>Injection</b>	Anti-IL-17 Receptor A Fully Human Antibody	Psoriasis	Filed in TW Filed in TH Filed in SG	Kirin-Amgen	
Other		<b>©KRN23</b> <b>Burosumab</b> <b>Injection</b>	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia (XLH)	Filed in EU		

Phase II, Phase III

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		<b>©RTA 402</b> <b>Bardoxolone Methyl</b> <b>Oral</b>	Antioxidant Inflammation Modulator	CKD in Patients with Type 2 Diabetes	Phase II in JP	Licensed from Reata	
Oncology		<b>©ARQ 197</b> <b>Tivantinib</b> <b>Oral</b>	c-Met Inhibitor	Hepatocellular Cancer	Phase III in JP	Licensed from ArQule	
		<b>KW-0761</b> <b>Mogamulizumab</b> <b>Injection</b>	Anti-CCR4 Humanized Antibody	Adult T-cell Leukemia/Lymphoma  Cutaneous T-cell Lymphoma	Phase II in US, EU and others  Phase III in US, EU, JP and others	In-House	POTELLIGENT®
Immunology /Allergy		<b>©KHK4083</b> <b>Injection</b>	Anti-OX40 Fully Human Antibody	Ulcerative Colitis	Phase II in US, EU and others		
		<b>©KHK4563</b> <b>Benralizumab</b> <b>Injection</b>	Anti-IL-5 Receptor Humanized Antibody	Asthma  Chronic Obstructive Pulmonary Disease (COPD)  Eosinophilic Chronic Rhin sinusitis (ECRS)	Phase III in JP and KR  Phase III in JP  Phase II in JP	In-House	POTELLIGENT®  Jointly Developed with AstraZeneca/MedImmune
		<b>KHK4827</b> <b>Brodalumab</b> <b>Injection</b>	Anti-IL-17 Receptor A Fully Human Antibody	Psoriasis  Axial Spondyloarthritis (axSpA)	Phase III in KR  Phase III in JP, KR and TW		
		<b>©ASKP1240</b> <b>Bleselumab</b> <b>Injection</b>	Anti-CD40 Fully Human Antibody	Recurrence of Focal Segmental Glomerulosclerosis (FSGS) in <i>de</i> <i>novo</i> kidney transplant recipients	Phase II in US	In-House	Human Antibody-Producing Technology Jointly Developed with Astellas
Central Nervous System		<b>KW-0761</b> <b>Mogamulizumab</b> <b>Injection</b>	Anti-CCR4 Humanized Antibody	HTLV-1 associated myelopathy (HAM)	Phase III in JP	In-House	POTELLIGENT®
		<b>KW-6002</b> <b>Istradefylline</b> <b>Oral</b>	Adenosine A <sub>2A</sub> Receptor Antagonist	Parkinson's Disease	Phase III in US, CA, EU and others	In-House	
		<b>©KW-6356</b> <b>Oral</b>	Adenosine A <sub>2A</sub> Receptor Antagonist	Parkinson's Disease	Phase II in JP	In-House	
Other		<b>©KRN23</b> <b>Burosumab</b> <b>Injection</b>	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia (XLH) in adult patients	Phase III in US, CA, EU, JP and KR	In-House	Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU
				X-linked Hypophosphatemia (XLH) in pediatric patients	Phase III in US, CA, EU, AU, JP and KR		
		<b>AMG531</b> <b>Romiplostim</b> <b>Injection</b>	Thrombopoietin Receptor Agonist	Aplastic Anemia  Idiopathic (Immune) Thrombocytopenic Purpura	Phase II in US  Phase II in JP and KR  Phase II / III in JP and KR  Phase III in CN	Kirin-Amgen	

 Updated since Jun. 30th, 2017 (Area, Stage, Filed, Approved, etc.)  
 New Molecular Entity

Ph I  antibody  protein  small molecule As of Sep.30, 2017

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		©KHK2375 Entinostat Oral	HDAC Inhibitor	Breast Cancer	Phase I in JP	Syndax	
		©KHK2455 Oral	IDO 1 Inhibitor	Solid Tumor	Phase I in US	In-House	Combination with KW-0761
		©KHK2823 Injection	Anti-CD123 Fully Human Antibody	Cancer	Phase I in UK	In-House	POTELLIGENT® Human Antibody-Producing Technology
		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Solid Tumor	Phase I in US	In-House	POTELLIGENT® Combination with Durvalumab/Tremelimumab (Jointly Developed with AstraZeneca)
	Phase I / II in US				Combination with Docetaxel		
Phase I in JP	Combination with Nivolumab (Jointly Developed with Ono Pharmaceutical)						
Immunology /Allergy		©KHK4083 Injection	Anti-OX40 Fully Human Antibody	Ulcerative Colitis Atopic Dermatitis	Phase I in JP Phase I in JP	In-House	POTELLIGENT® Human Antibody-Producing Technology
Central Nervous System		©KHK6640 Injection	Anti-Amyloid Beta Peptide Antibody	Alzheimer's Disease	Phase I in EU Phase I in JP	Licensed from Immunas Pharma	
Others		KW-3357 Antithrombin Gamma Injection	Recombinant Human Antithrombin	Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency	Phase I in EU	In-House	

 Updated since Jun. 30th, 2017 (Area, Stage, Filed, Approved, etc.)  
 New Molecular Entity

Updated since Jun. 30th, 2017 (Area, Stage, Filed, Approved, etc.)

## Filed • Approved

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Immunology /Allergy		KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Psoriasis	Filed in SG	Kirin-Amgen	